Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05221304 in adults with nonalcoholic fatty liver disease
2017-001156-55Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) comparing PF-05221304 dose-ranging arms with Placebo (2 arms). Primary endpoint: Percent change from baseline in liver fat. Started Sep 2017; status: completed.
02
Drugs
clesacostat
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2017-001156-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001156-55.